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dentification of the biological concomitants of
psychiatric illnesses such as schizophrenia is a goal that is
pursued for a variety of purposes.First is the hope that,as
in other branches of medicine,biological measurements
or markers will increase the precision of diagnosis.Second
is the possible usefulness of the markers to subtype
groups that may respond to particular medications and to
monitor the progress of the treatment.A third hope,the
subject of this essay, is the possibility that a biological
process will be observable before the onset of illness,so
that vulnerable individuals can be identified early and
perhaps treated before the full development of psy-
chopathology.If there were markers that fulfilled the first
two criteria,then it would be straightforward to consider
their use for early identification and preventive treatment.
However,no biological marker has yet been recognized
that definitively fulfills any one of these criteria,so that
the application to prevention has remained uncertain.This
paper will suggest that the failure to find biological mark-
ers that fit the first two criteria is a consequence of the
complex, multidetermined pathophysiology of major
mental disorders,but that this failure does not preclude
the possibility that biomarkers will be helpful in design-
ing strategies for prevention of schizophrenia.
The use of a biological marker to identify someone as ill
prior to the onset of clinically detectable symptoms car-
ries enormous responsibility when the illness is expected
to be serious and not amenable to a curative treatment.
Even if the marker has high validity,examination of indi-
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Biological traits that are predictive of the later develop-
ment of psychosis have not yet been identified. The com-
plex, multidetermined nature of schizophrenia and other
psychoses makes it unlikely that any single biomarker will
be both sensitive and specific enough to unambiguously
identify individuals who will later become psychotic.
However, current genetic research has begun to identify
genes associated with schizophrenia, some of which have
phenotypes that appear early in life. While these pheno-
types have low predictive power for identifying individu-
als who will become psychotic, they do serve as biomark-
ers for pathophysiological processes that can become the
targets of prevention strategies. Examples are given from
work on the role of the  7-nicotinic receptor and its gene
CHRNA7 on chromosome 15 in the neurobiology and
genetic transmission of schizophrenia.  
© 2005, LLS SAS Dialogues Clin Neurosci. 2005;7:17-29.vidual persons for its presence would be ethically prob-
lematic.When the marker has lower validity,the ethical
problem would seem to be increased.Specifically,label-
ing of a child as a future schizophrenic based on our pre-
sent understanding of the biology of the illness seems
unconscionable. Nevertheless, biological markers may
indicate the presence of a pathophysiological process that
can be addressed with a preventive treatment.Therefore,
the identification of biomarkers prior to onset of psy-
chosis has enormous potential importance for the design
of future preventive strategies.The success of preventive
treatments such as prenatal folic acid supplementation
for a wide variety of conditions,including cleft palate and
neural tube defects,suggests that early intervention may
be surprisingly effective and often relatively benign,so
that prevention could be applied to individuals for whom
there is little certainty that they would have disease in the
future.Thus,a paradox is that identification of biomark-
ers for predictive purposes,which may be unethical,does
not preclude their ethical use for the design of preven-
tion strategies.
Most cases of schizophrenia occur during late adoles-
cence and early adulthood.Although there is often a pro-
drome during which signs of illness are present, most
individuals who develop schizophrenia have had some
period,generally from childhood through early adoles-
cence,during which they did not have enough symptoms
to be declared ill.
1The question relevant to the search for
early biomarkers is whether the neurobiological sub-
strates of illness are already present,perhaps from birth,
and only awaiting adolescence to become manifest as a
clinical behavioral syndrome or whether adolescence
itself somehow causes the illness.Despite the profound
biological change that accompanies adolescence,mental
illness stands out as the only major category of illness
that occurs during the transition into adulthood.
Therefore,one goal for the investigation of biomarkers
is to use them to establish when during development the
pathophysiological defects associated with schizophrenia
first occur, so that the appropriate window of time for
intervention can be identified.
The emphasis on the genetic basis of schizophrenia and
other major mental disorders suggests that a similar
emphasis on genetic factors should influence the search
for early biomarkers for psychosis.In contrast to the peak
incidence of schizophrenia in late adolescence,genetic
factors are obviously present from conception,and their
neurobiological expression could therefore begin as early
as the fetal period. In fact, more genes are expressed
more robustly during fetal development than at any
other time during the life cycle,so that a reasonable pre-
sumption is that their maximal effect would be expected
in that period.Few of the currently investigated candi-
date genes for schizophrenia or bipolar disorder have
expression patterns that suggest maximal influence at
any other time during the life cycle.Therefore,it is rea-
sonable to search for biological markers as early as dur-
ing the period of fetal development.
Genetic risk for schizophrenia
While genetic risk is certainly a reasonable clue to follow
to search for the developmental biomarkers of schizo-
phrenia, there are inherent difficulties in this strategy.
Schizophrenia is a genetically complex illness.Although
the heritability for schizophrenia is estimated to be as
high as 70%,the illness clearly does not have a pattern
of inheritance in any population or even in single fami-
lies that is consistent with the effect of a single gene.Thus,
like many common illnesses such as diabetes and hyper-
tension,it is more likely that multiple genes are involved.
Multigenic illnesses were once considered unanalyzable
by genetic linkage techniques,but the use of large sam-
ple sizes,dense chromosomal maps,and improved statis-
tical methodology has led to the detection of a number
of genetic loci.For some of these loci,promising candi-
date genes have been identified and,for some of these
genes, polymorphisms have been discovered that are
associated with schizophrenia and would seem to alter
gene function to produce a neurobiological effect.Most
of the genes identified have some role in the develop-
ment or function of neurotransmission.
Consideration of the finding of multigenic inheritance
illuminates the problem of detecting biomarkers for
schizophrenia. For example, if two genes on different
chromosomes are hypothesized to be responsible for all
cases of schizophrenia,then,for 1% of the population to
have schizophrenia,the frequency of the allele associated
with schizophrenia must be approximately 5% per chro-
mosome for each gene.An individual would then have
5% chance of inheriting a disease allele for the first gene
from mother and 5% from father,for a total of approxi-
mately 10%.For the second gene,a similar consideration
applies.The combined probability of inheriting disease
alleles in both genes would be 10% times 10%, or 1%
total risk.If a parent had schizophrenia,so that he or she
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transmitting both would be 50% for each disease allele,
since one of two chromosomes,one carrying the disease-
associated allele and one not, is transmitted to an off-
spring through the sperm or egg.The probability of trans-
mitting disease alleles for both genes would be 50%
times 50%,or 25%.Since the observed transmission of
risk from parent to child is only about 10%, the actual
genetic structure is more complicated than a simple two-
gene model.However,the two-gene model comes closer
than a one-gene model,for which parent–child transmis-
sion would be 50%. Additional complexities could
include the involvement of more than two genes or envi-
ronmental factors to produce the illness, which could
range from perinatal developmental injury to psychoso-
cial stressors.
The implication of this theoretical exercise for the early
assessment of risk factors is that disease allele frequencies
of 5% per chromosome (termed the allele frequency) or
about 10% per individual,considering the possibility of
the occurrence of a disease allele on either of the two
chromosomes,mean that a biomarker associated with a
specific gene would occur in about 10% of the population.
Thus,even if we perfectly understood both the molecular
biology and the associated neurobiological deficits for one
of the genes that convey risk for schizophrenia,and if that
gene were involved in all cases of schizophrenia,then we
would still detect its presence in 10% of the population,
which would include the 1% who would actually develop
schizophrenia.Treatment of 10% of adolescents with neu-
roleptic drugs,to delay the onset of psychotic symptoms
that might occur in only 1 out of 10 of the identified indi-
viduals would probably be viewed as medically unsound
from the perspective of risk and benefit.Of course,if we
could identify all the genes and all their interactions with
each other and with environmental factors,then we might
be able to restrict the identification to a subset of indi-
viduals who were more likely to develop schizophrenia,
but such a complete understanding has not yet been
achieved.
The actual findings with genetic linkages and candidate
genes associated with risk for schizophrenia suggest that
the theoretical two-gene exercise underestimates the
prevalence of genetic risk in the population.For exam-
ple,we have conducted genetic linkage analysis for schiz-
ophrenia in the National Institute of Mental Health
(NIMH) Genetics Initiative families.
2The first 88 fami-
lies were selected to have two ill individuals,generally a
pair of siblings,who met the then current diagnostic cri-
teria (Diagnostic and Statistical Manual of Mental
Disorders,Third Edition,Revised [DSM-III-R]) for schiz-
ophrenia or schizoaffective disorder, with at least one
individual meeting criteria for schizophrenia.The fami-
lies were collected by a consortium of investigators at
Harvard University, Washington University, and
Columbia University,and the genotyping was performed
by Millennium Pharmaceuticals.Several genetic analyses
of the sample have been published,which point to loci on
a number of chromosomes.A maximum likelihood sta-
tistical analysis was used to determine the association
between genetic markers on each of the chromosomes
and the inheritance pattern of the illness in each family.
The analysis determined the common logarithm of the
ratio of the odds that there is a true linkage between
chromosomal markers and the illness, as opposed to a
chance association,termed the LOD score.Scores above
3.3 are considered indicative of linkage,through lower
LOD scores also considered worthy of further investiga-
tion.Chromosomes 15 and 10 contain two of the more
significance loci (Table I).
Significance of a linkage finding is based on several fac-
tors,the most relevant of which is the pathophysiological
significance of the underlying putative genetic variant
that causes the illness.Genetic linkage does not directly
identify the variant;rather,it finds genetic markers that
are close to or linked to an undiscovered genetic variant
that actually contributes to risk for the illness.Thus,other
factors can equally influence the LOD score, such as
genetic homogeneity of the population,so that the num-
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Table I. Genetic linkage in the National Institute of Mental Health (NIMH)
pedigrees. Autosomal dominant model f(A)=0.0045. The HLOD
is the LOD score under the assumption of genetic heterogene-
ity, ie, different genetic loci responsible for transmission of schiz-
ophrenia in different subgroups of families. The scores were com-
puted using pairs of adjacent genetic markers. α is the estimate
from the heterogeneity analysis of the proportion of linked pedi-
grees at any given locus.
Locus HLOD score (α )
6q13-21 1.11 (0.35)
9q32 1.09 (0.40)
10p13 2.40 (0.45)
13q32 0.58 (0.25)
15q14 3.97 (0.95)
15q21 1.00 (0.50)
17p13 0.93 (0.40)
20q13 1.56 (0.45)ber of other possible genetic causes of schizophrenia in
the population is limited.Accordingly,although findings
with chromosomes 15 and 10 have been replicated in
other populations,there are considerable differences in
genetic findings for schizophrenia across different popu-
lations and studies.Thus,the selection of chromosomal
loci in this example is only one of several strategies that
could be used.
The more powerful genetic analytic strategies use like-
lihood analyses that assume a model of inheritance,
which can be either dominant or recessive.Additional
parameters that are specified are the allele frequency of
each putative allele and the penetrances,which are the
probability that each putative genotype will produce ill-
ness.Thus,if A and a are two alleles of a putative gene
associated with risk for schizophrenia,and the A variant
is associated with risk and the a variant is not, there
would be four possible genotypes if we list the paternally
inherited allele, followed by the maternally inherited
allele:AA,aa,Aa,and aA.The frequency of each geno-
type is the product of the two allele frequencies. For a
dominant genetic model with complete penetrance,the
penetrance is 1.0 for any genotype containing A.For a
gene with only two alleles,the two allele frequencies add
to 1.0,and the sum of the products of the penetrances of
each genotype and the frequency of each genotype is the
frequency of the illness in the general population.The
frequency of the illness in the general population (0.01)
is a piece of real data that anchors the model in reality.
Thus,in the example in Table II,the sum of the gene fre-
quencies, which are the products of the two allele fre-
quencies, is 1, accounting for all genotypes.The pene-
trances of the three genotypes that contain A,either as
the homozygote AA or the heterozygotes Aa and aA,are
1.0, because this is a completely dominant illness.The
penetrance of aa,a genotype that does not convey risk,
is 0.00103,which essentially accounts for the possibility
of other genetic and nongenetic causes of illness that do
not involve this gene.The sum of the product of the gene
frequencies is 0.01, which is the frequency of schizo-
phrenia in the population.These parameters were used
in the initial analyses for a Canadian linkage study that
identified a locus on chromosome 1 with the highest sta-
tistical confidence level yet reported for a genetic link-
age finding in schizophrenia.
3 The assumptions of the
model,in addition to dominant transmission,is that the
gene that conveys risk for schizophrenia is highly pene-
trant so that the genotypes containing A always produce
illness and there are very few cases (1/10) that do not
have this particular genetic cause.The model posits that
schizophrenia is caused by a gene that has an extremely
deleterious effect on brain function,resulting in a very
severe illness,chronic schizophrenia.A similar model has
been used to discover other major genetic influences in
schizophrenia.
4 In the Canadian study,it turned out that
a similar recessive model better explained the data.
Returning to the NIMH families,the finding of multiple
genetic signal calls this simple model into question.
Considering only the two most positive linkages,chro-
mosomes 15 and 10,there would seem to be two possi-
bilities. One possibility is that there are two types of
schizophrenia,a 15 type and a 10 type,where the data are
best explained as two independent findings,with some
families having one type and some having another,a het-
erogeneous model. A second possibility is that both
genetic factors are active in the same families and that
schizophrenia results from their additive effect. This
model implies that neither gene by itself produces an
effect that is completely devastating to normal brain
function, but when deficits from the two genes occur
together,a threshold is crossed,and a brain dysfunction
occurs that results in psychosis. The genetic model
becomes more complex,but the products of genotypes
and penetrances must still add to 0.01,the population fre-
quency of schizophrenia (Table III). For the additive
model,if we allow the frequency of the putative disease
variants in each of the two genes to vary,we see that the
maximum likelihood occurs with much higher allele fre-
quencies than the 0.0045 frequency that we initially
assumed (Figure 1).At this high frequency,penetrance is
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Table II. An autosomal dominant model of schizophrenia for a single gene.
Genotype Allele frequency Gene frequency Penetrance Proportion affected
AA 0.0045× 0.0045 0.00002025 1 0.00002
Aa 0.0045× 0.9955 0.00447975 1 0.00448
aA 0.9955× 0.0045 0.00447975 1 0.00448
aa 0.9955× 0.9955 0.99102025 0.00103 0.00102
1.00000000 0.01000also reduced (Table III),indicating that individuals who
carry the genotypes associated with illness now have only
a 25% probability of having the illness.A comparison of
this additive model with the heterogeneous model, by
subtracting their respective maximum likelihood,reveals
that the additive model is significantly more likely.Thus,
genetic linkage data in the NIMH population supports
the hypothesis that schizophrenia is caused by multiple
genes acting together and the variants associated with the
illness are common in the population.
This hypothesis is further supported by another type of
genetic data.For many of the linkage signals,candidate
genes are now being identified.At chromosomal region
15q14, the most extensively studied candidate gene is
CHRNA7, the gene for the α 7-nicotinic acetylcholine
receptor.This gene was first identified by neurobiological
research into a pathophysiological abnormality in schizo-
phrenia, the failure to inhibit the P50 auditory evoked
response to the second of paired stimuli.
5This inhibitory
deficit, one of many such physiological sensory gating
deficits characterized in schizophrenia, is related to
patients’ inability to maintain sustained attention,one of
the notable neuropsychological deficits of schizophrenia.
These sensory gating deficits have been related clinically
to patients’ filtering deficits.
6 They describe being over-
whelmed or flooded by sensory stimuli in their environ-
ment that most normal subjects can ignore.Deficits in pre-
pulse inhibition of startle, poor performance in the
continuous performance test,and various smooth pursuit
eye tracking abnormalities have all been characterized as
failures in inhibitory and sensory gating function in schiz-
ophrenia.Deficits in inhibitory neurons,including failures
of migration,diminished expression of inhibitory neuro-
transmitters,and loss of the neurons themselves,have all
been found in postmortem studies of brain tissue for per-
sons who had schizophrenia.
7 Deficits in expression of α 7-
nicotinic receptors,which are highly expressed on many
interneurons,are consistent with the other deficits found
in these interneurons. Animal models with genetically
diminished expression of the α 7-nicotinic receptor have
deficits in inhibition of auditory evoked responses that
resemble the deficit in schizophrenia.
8These models sug-
gest that nicotinic receptor activation of interneurons in
the hippocampus is a critical mechanism in sensory inhi-
bition.Thus,deficits in inhibition in general and diminished
nicotinic receptor activation of inhibitory interneurons in
particular appear to be two of the neurobiological features
of schizophrenia (Figure 2).
Genome-wide linkage studies initially related the loss of
P50 inhibition in schizophrenia to the chromosomal
region 15q14 locus of CHRNA7.Mutating screening in
the CHRNA7 gene resulted in the discovery of single
nucleotide polymorphisms in the promoter and other
abnormalities that have been associated with schizo-
phrenia itself and also with the failure to inhibit P50
responses in schizophrenia (Figure 3).While the signifi-
cance of all of these polymorphisms is still being sorted
out,the allele frequency of these polymorphisms is rel-
atively high, as was predicted from the linkage data.
9
Similarly high frequencies have been reported for most
other putative candidate genes for schizophrenia.
10
Taking all these genes into account,it would seem that
the majority of the population has at least one of the
genetic risk factors for schizophrenia.
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Table III. A model of schizophrenia requiring two genetic loci.
Penetrances for multigenic threshold model (fA=0.1; fB=0.1)
Trait locus 1
AA Aa aa
BB 0.25 0.25 0.001
Trait locus 2 Bb 0.25 0.25 0.001
bb 0.001 0.001 0.001
Figure 1. Relationship of maximum LOD score to gene frequencies for two
locus linkage to schizophrenia. This model produces a peak LOD
score at allele frequencies of 0.1, which is significantly greater
than the score derived from the heterogeneous model (Chi-
square=14.54; df=1; P=0.000069). 
Reproduced from reference 2: Freedman R, Leonard S, Olincy A, et al.
Evidence for the multigenic inheritance of schizophrenia. Am J Med
Genet. 2001;105:794-800. Copyright © 2001, Wiley-Liss, Inc.
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Two lociThus, the somewhat unexpected result of genetic
research to date is that genetic risk is much more wide-
spread than initially posited.Identification of individuals
at risk by genetic means alone is not likely to select indi-
viduals who have a high probability of actually develop-
ing schizophrenia.However,the situation is not as hope-
less from the perspective of prevention. First, for
CHRNA7 and for many of the other genes being discov-
ered for schizophrenia,the neurobiological phenotypes
are being elucidated. Most of the genes are associated
with dysfunction in the mechanisms of neurotransmis-
sion. For CHRNA7, there is an apparent link to an
inhibitory dysfunction that can be measured physiolog-
ically,in both animal models and humans.To the extent
that this dysfunction and similar dysfunctions can be
traced through development,a biological developmental
course of schizophrenia can be ascertained,so that the
window for possible prevention can be determined.
While this time course could have been established with-
out the genetic information,the genetic associations and
linkages relate the physiological dysfunction,eg,dimin-
ished sensory gating,to a well-identified biological ele-
ment,eg,diminished activation of α 7-nicotinic receptors.
The dominant model with complete penetrance posited
a model of pathophysiology in which a single genetic
deficit produces a near catastrophic effect on brain func-
tion that results in schizophrenia. The more complex
model posited here suggests that schizophrenia may be
the coincidence in a single individual of multiple deficits,
none of which in themselves are particularly problematic.
Small changes in the pathophysiological effect of any one
of these deficits could have significant effects on the
development of illness.
The developmental time course of 
physiological dysfunction in schizophrenia
In adolescence,persons at risk for schizophrenia can be
identified in two ways—by the individual having a par-
ent who has schizophrenia,particularly in a family that
already has other cases of schizophrenia,or by the indi-
vidual displaying prodromal features of schizophrenia.
Palau is a small island nation in Micronesia in which
many individuals with schizophrenia have been found in
Basic research
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Figure 2. Neurophysiological studies of the P50 sensory gating phenom-
ena have implicated the pyramidal neurons of the hippocampus
as a source of the wave. Interneurons in the hippocampus are
responsible for inhibition of pyramidal neuron response in the
conditioning-testing or paired stimulus paradigm. These
interneurons are excited by cholinergic innervation via α 7-nico-
tinic cholinergic receptors and inhibited by adrenergic receptors.
GABA, γ -aminobutyric acid.
Glutamate
GABAB
presynaptic receptor
GABA
α 1-Noradrenergic
receptor
α 7-Nicotinic
cholinergic
receptor
Figure 3. Effects of a single nucleotide polymorphism in the promoter of
CHRNA7 on P50 sensory gating. The normal subject with more
common alleles (-86 C/C) has normal suppression of P50, mea-
sured as a low P50 test to conditioning amplitude ratio. The sub-
jects with the polymorphism (-86 C/T) have higher, more abnor-
mal ratios. The physiological abnormality is expressed regardless
of whether the subject is normal or has schizophrenia.  
Reproduced from reference 9: Leonard S, Gault J, Hopkins J, et al.
Association of promoter variants in the α 7-nicotinic acetylcholine receptor
subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen
Psychiatry. 2002;59:1085-1096. Copyright © 2002, American Medical
Association.
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large, multiply affected families. Adolescents in these
families have an elevated prevalence of diminished P50
inhibition.Adolescents identified by self-report and fol-
low-up interview as displaying prodromal symptoms also
have an elevated prevalence of diminished P50 inhibi-
tion.
11Thus,diminished P50 inhibition is present in ado-
lescents at risk for schizophrenia before the onset of psy-
chotic symptoms (Figure 4).
Attempts to measure P50 in younger children have
shown that normal adult levels of P50 inhibition are pre-
sent in only about half of preadolescent children.In these
younger children,diminished levels of inhibition do not
correlate with any obvious psychopathology or familial
risk.Rather,the children with diminished P50 inhibition
tend to display increased levels of activity that are well
within the normal range for children of their age. P50
inhibition is not solely determined by linkage to
CHRNA7.Adrenergic activity,for example,diminishes
inhibitory interneuron response and is correlated with
diminished P50 inhibition in normals. While it is not
known whether normal children with diminished P50
inhibition have increased adrenergic activity,it is known
that children are much better able than adults to tolerate
psychotomimetic drugs,such as amphetamine and keta-
mine,both of which increase catecholaminergic activity.
Whether the apparent maturation of P50 inhibition at the
end of adolescence and the loss of relative protection
against psychotomimetic effects of drugs and the peak
incidence of development of schizophrenia during this
transition to adulthood have a common neurobiological
basis is a question that has yet to be addressed.
Adrenergic activity itself varies considerably with the
state of alertness and stress.Experimental elimination of
adrenergic activity by pharmacological means in animals
results in the normalization of the inhibition of auditory
responses to repeated stimuli. Similar experiments in
normal children would be informative about the neuro-
biology of P50 inhibition,but exposure of these children
to medication is problematic.However,loss of adrener-
gic activity is one of the physiological concomitants of
rapid eye movement (REM) sleep.Therefore,a natural
state exists in which P50 inhibition can be measured with-
out the interference of adrenergic activity. In adults,
recordings during REM show the same differences in
P50 inhibition between normals and schizophrenics that
have been observed during the waking state.
12 For school-
aged children, the REM state would also be achieved
after sleep deprivation or by all-night recording,but for
newborns,REM is a frequently achieved state during the
day.Therefore,we have recorded P50 inhibition during
the first 3 months of life.
In initial experiments,infants could indeed be recorded
during REM sleep and P50 responses were elicited.
13The
degree of inhibition was correlated with gestational age,
calculated from conception.This method is used to avoid
the confound of premature birth in the calculation of
perinatal development.By the first 3 months of life,most
infants have developed near-adult levels of P50 inhibi-
tion (Figure 5).Recording of infants at risk for schizo-
phrenia is a logical next step in determining whether or
not the neurobiological processes that result in abnormal
P50 inhibition in schizophrenia are present as early as the
neonatal period.
Other inhibitory dysfunctions associated with schizo-
phrenia are also present during childhood.Persons with
schizophrenia have abnormal smooth pursuit eye move-
ment tracking. The task consists of following a slowly
moving target,which the subject must follow with his or
her eyes, while eye movement is monitored using
infrared reflectometry.Normal persons are able to move
their eyes precisely,so that the image of the target always
remains in the small foveal region of the retina.Persons
with schizophrenia and some of their relatives have
Figure 4. Percentages of P50 ratios in the abnormal range (amplitude
of test wave/amplitude of conditioning wave>0.5) is elevated
in adolescents with prodromal symptoms of schizophrenia or
with first-degree relatives who have schizophrenia. Data are
from a study conducted on the island Palau by Myles-Worsley
et al.
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70diminished performance of the task.One of the elements
of this abnormality is the inability to inhibit saccadic eye
movements,so that their eyes jump ahead of the target
and then wait for the target to catch up (Figure 6).
Functional magnetic resonance imaging during the task
reveals increased hemodynamic activity in the hip-
pocampus (Figure 7).
14This increased activity is consis-
tent with the putative decreased hippocampal inhibition
that has also been proposed as a mechanism for the
diminished inhibitory gating of the P50 response.
15
About half of children with a parent who has schizo-
phrenia also have abnormal smooth pursuit eye move-
ments with the intrusion of saccades, which can be
detected as early as age 6.
16This abnormality is thus the
earliest studied physiological dysfunction associated with
the eventual appearance of schizophrenia (Figure 8).The
abnormality is associated with neuropsychological evi-
Basic research
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Figure 5. Relationship between age and selected electrophysiological vari-
ables. A. P50 T/C ratio generally decreases (ie, sensory gating
improves) with advancing age. B. Electroencephalogram (EEG)
spectral power in the θ band (4-8 Hz), associated with rapid-eye
movement (REM) sleep in the hippocampus, also increases in the
same time period.  
Reproduced from reference 12: Kisley MA, Olincy A, Robbins E, et al.
Sensory gating impairment associated with schizophrenia persists into
REM sleep. Psychophysiology. 2003;40:29-38. Copyright © 2003,
Blackwell Publishing.
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Figure 6. In schizophrenia, there are several abnormalities in smooth pur-
suit eye movements. One of these is elevated frequency of antic-
ipatory saccades, the failure to inhibit fast or saccadic eye move-
ments that cause the eyes to jump ahead of the slowly moving
target. Broken line, target position; unbroken line, eye position.
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Figure 7. Functional magnetic resonance imaging of 14 schizophrenics
and 14 normals performing smooth pursuit eye movements. The
images are comparisons between the two groups. The schizo-
phrenics have increased hemodynamic activity in the hip-
pocampus, consistent with loss of inhibition.   
Reproduced from reference 14: Tregellas JR, Tanabe JL, Miller DE, Ross
RG, Olincy A, Freedman R. Neurobiology of smooth pursuit eye move-
ment deficits in schizophrenia: an fMRI study. Am J Psychiatry.
2004;161:315-321. Copyright © 2004, American Psychiatric Association.
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6dence of attention dysfunction, one of the cognitive
abnormalities found in children at risk for schizophrenia.
17
Thus,the use of physiological dysfunctions associated with
the genetic risk for schizophrenia to identify putative win-
dows during which preventive efforts might be possible
points to the expression of these dysfunctions before the
onset of schizophrenia.Dysfunction is certainly present in
adolescents at risk and in school-aged children, but the
development of inhibitory function in the early perinatal
period suggests that it is reasonable to look even earlier.
The developmental effects of 
gene dysfunction
The identification of a window for a developmental effect
is a major clue to the mechanism of developmental
abnormality in schizophrenia, but it does not immedi-
ately identify possible mechanisms.An advantage of a
genetically associated pathophysiological feature is that
the cellular mechanism can be immediately deduced
from the gene’s product.Most of this work is necessarily
performed in animal models, because neurobiological
investigation at the cellular level cannot generally be per-
formed in human beings.As in the previous section,the
example will come from our work on CHRNA7 and
inhibitory brain mechanisms, but similar examples are
possible with many of the other genes currently being
investigated for schizophrenia.α 7-Nicotinic receptors are
formed early in development,when neurons first differ-
entiate from the neuroepithelium. During adult life in
rodents,the expression is particularly marked in the hip-
pocampus.
18,19 In primates including humans, there is
prominent expression in the hippocampus as well, but
also in the cingulate cortex and in the nucleus reticularis
thalami,which is a thin sheet of inhibitory neurons that
surrounds the thalamus.
20 In rodents and in humans,hip-
pocampal pyramidal neurons have diminished response
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Figure 8. Admixture analysis of the frequency (per minute) of leading sac-
cades during a smooth-pursuit eye movement task in 189 chil-
dren, aged 6 to 15 years. For the typically developing children,
81% perform in the lowest (best-performing) mode and 19%
in the moderately elevated mode. First-degree relatives of per-
sons with schizophrenia are equally distributed, with 50% in the
lowest mode and 50% in the moderately elevated mode. For
children who have schizophrenia, 6% have leading saccade fre-
quencies in the lowest mode, 86% in the moderately elevated
mode, and 8% in the severely elevated mode.   
Reproduced from reference 16: Ross RG. Early expression of a patho-
physiological feature of schizophrenia: saccadic intrusions into smooth-
pursuit eye movements in school-age children vulnerable to schizophre-
nia. J Am Acad Child Adolescent Psychiatry. 2003;42:468-476. Copyright
© 2003, Lippincott, Williams and Wilkins.
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Figure 9. Dual labeling with an antibody for the inhibitory neurotrans-
mitter GABA (left) and radioactive α -bungarotoxin (right), which
labels α 7-nicotinic receptors, demonstrates expression of these
receptors on inhibitory interneurons in the rat hippocampus. For
other examples, see reference 1. GABA, γ -aminobutyric acid.   to repeated stimuli,making the hippocampus is a puta-
tive source of the diminished P50 response to repeated
stimuli that can be modeled in rodents.
15 α 7-Nicotinic
receptors are found both presynaptically and postsynap-
tically throughout the hippocampus, the area studied
most thoroughly at the ultrastructural level using elec-
tron microscopy.α 7-Nicotinic receptors are found within
glutamate synapses,where they anchor to common post-
synaptic densities.
21 However, the most prominent
expression is postsynaptic on interneurons throughout
the hippocampus (Figure 9).During perinatal develop-
ment there is also prominent expression on pyramidal
neurons in the CA1 region,but this expression soon dis-
appears early in postnatal development.
22 Indeed, the
perinatal expression of α 7-nicotinic receptors is greater
than at any other time during the life cycle (Figure 10).
The DBA/2 inbred mouse strain has lower levels of α 7-
receptors in the hippocampus and diminished inhibition
of the hippocampal evoked response to the repeated
auditory stimuli. Although P50 has several sources in
human brain,it can be recorded from the hippocampus.
The DBA/2 mouse also has polymorphisms in the
CHRNA7 gene, outside the amino acid coding region,
which correlate with diminished expression of the gene.
Thus,the DBA/2 mouse mimics pathophysiological fea-
tures found in many persons with schizophrenia,ie,dimin-
ished expression of α 7-nicotinic receptors and polymor-
phisms in CHRNA7,as well as diminished inhibition of
the P50-type response to repeated stimuli.
8 In DBA/2
mice, the expression of α 7-nicotinic receptors is dimin-
ished in the CA3 region of the hippocampus,but is rela-
tively abundant in some areas of CA1.These differences
are maintained when the region of mouse chromosome 7
that contains CHRNA7 is selectively bred onto the
genetic backgrounds of other inbred strains of mice.
23
During development,DBA/2 mice lag behind compari-
son strains in the development of an adult pattern of α 7-
nicotinic receptor expression (Figure 11).
24
Like N-methyl-D-aspartate (NMDA)–type glutamate
receptors,activation of α 7-receptors admits calcium ions,
Basic research
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Figure 10. Expression of α 7-nicotinic receptors in the hippocampus, measured by labeling with α -bungarotoxin (α -BTX), in rats during early develop-
ment and adulthood.  
Reproduced from reference 23: Adams CE, Stitzel JA, Collins AC, Freedman R. α 7-Nicotinic receptor expression and the anatomical organization of hippocam-
pal interneurons. Brain Res. 2001;922:180-190. Copyright © 2001, Elsevier.
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Stratum lacunosum/moleculareas well as other cations,into neurons and thereby acti-
vates nitric oxide synthetase,to produce the second mes-
senger nitric oxide.
25 Presumably,this second messenger
system is part of the mechanism of the development of
neuronal circuitry that underlies reciprocal excitation and
inhibition in the hippocampus.Activation of the recep-
tors may be part of a complex maturation of gluta-
matergic synapses. Early in development, cholinergic
receptors can depolarize neurons before they receive glu-
tamatergic synapses,which eventually will become the
primary depolarizing or excitatory receptors of the cen-
tral nervous system.The depolarization produced by α 7-
receptors may thus be critical to early circuit formation
at about the time of birth,in both rodents and primates.
Indeed,DBA/2 mice,in addition to their deficiencies in
α 7-nicotinic receptors,have alterations in the expression
of glutamate receptors,eg,decreased AMPA (α -amino-
3-hydroxy-5-methyl-4-isoxazole proprionic acid) and
kainate receptors and increased NMDA receptors, a
pathological change that has also been found in the hip-
pocampus of schizophrenics.
26,27
Thus,developmental abnormalities in α 7-nicotinic recep-
tors may have effects beyond cholinergic neurotrans-
mission. These nicotinic developmental abnormalities
may affect the development of the major glutamatergic
pathways that support most information-processing
mechanisms in the brain.Several of the genes associated
with schizophrenia are involved in the formation of glu-
tamatergic synapses as well,suggesting that the develop-
ment of these synapses may be a final common pathway
for several genetic risk factors.
10 From the adult perspec-
tive,CHRNA7 deficiencies appear as elementary prob-
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Figure 11. Developmental time course of α 7-nicotinic receptors in DBA/2 mice (right) and a control strain, C3H (left). Prenatal days 13, 16, 17, and 18
are shown from top to bottom.
24 A. Binding for α -bungarotoxin (α -BTX) is initially observed in the dorsal portion of the hippocampal anlage
of C3H mice on embryonic day 13 (E13). Binding is both diffuse (arrowheads) and clumped (arrows) in appearance. No α -BTX binding is
observed in the neuroepithelium (NE). B. Binding of α -BTX is not detectable in the developing hippocampus of DBA/2 mice on E13. C. Binding
of α -BTX is increased in density and is present in both hippocampal areas CA1 and CA3 of the C3H mouse strain on E16, but not in the
immature dentate gyrus (D). The pattern of hippocampal α -BTX binding is again comprised of a mixture of diffuse (arrowheads) and clumped
(arrows) silver grains. D. Binding of α -BTX is initially detected in the hippocampal formation of DBA/2 mice on E16. The level of binding is
higher in area CA3 than in area CA1, while no binding is observed in the dentate gyrus. Scattered clumps of silver grains (arrows) are seen
within a more diffuse background (arrowheads). Overall, the level of α -BTX binding in DBA/2 mouse hippocampus on E16 is much lower
than that observed in C3H mouse hippocampus at the same age. E. Binding of α -BTX is increased in density in hippocampal areas CA1 and
CA3 and is initially detected in the dentate gyrus (D) on E17 in C3H mice (arrowheads). F. The level of α -BTX binding is also increased in hip-
pocampal areas CA1 and CA3 in DBA/2 mice on E17, but is not detectable in the dentate gyrus. G. A marked increase in the density of 
α -BTX binding is seen in hippocampal area CA1 of C3H mice on E18, especially at the border between stratum pyramidale and stratum
radiatum of area CA1 (arrows). α -BTX binding density is also increased in hippocampal area CA3 and in the dentate gyrus of C3H mice at
this stage of development. H. Binding of α -BTX is initially observed (arrowheads) in the dentate gyrus (D) of DBA/2 mice on E18. An increase
in the density of α -BTX binding is also seen in both hippocampal areas CA1 and CA3 of DBA/2 mice at this age, although binding levels are
still greater in area CA3 than in area CA1. Calibration bar =120 mm. 
Reproduced from reference 24: Adams CE. Comparison of α 7-nicotinic acetylcholine receptor development in the hippocampal formation of C3H and DBA/2
mice. Brain Res Dev Brain Res. 2003;143:137-149. Copyright © 2003, Elsevier.Basic research
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lems in inhibition,which have neurocognitive significance
for the individual. However, from the neurodevelop-
mental perspective,CHRNA7 deficiencies could have a
profound effect on the development of the excitatory and
inhibitory synapses.Thus,remediation of CHRNA7 defi-
ciencies in adult life by pharmacological means might not
sufficiently reverse their developmental insult.
Significance for possible interventions
The significance of developmental pathophysiology for
the prevention of schizophrenia is the possibility that an
intervention can be performed at some time in the life
cycle before the onset of schizophrenia,possibly in the
perinatal period.Whether a strategy to activate nicotinic
cholinergic receptors can be formulated and whether it
would be effective in all cases or only in individuals who
have polymorphisms in CHRNA7 receptors is unknown.
Biomarkers such as diminished P50 inhibition or saccadic
intrusions into smooth pursuit eye movements could be
helpful to establish the timing and effectiveness of the
intervention. More generally, the identification of the
time course and cellular mechanism of developmental
abnormalities associated with schizophrenia thus has the
potential to identify possible strategies for reversal of
these developmental abnormalities. Pharmacological
strategies to activate deficient receptors or to replace
deficient growth factors are within the range of current
biological possibilities. As genetic information about
schizophrenia and other mental disorders increases,the
possibilities for such interventions are likely to increase.
In some cases, the genetic information may indicate
unique mechanisms,but in other cases the mechanisms
may converge to common targets,such as the develop-
ment of excitatory and inhibitory synapses.
The use of biomarkers for studies of the development of
schizophrenia can thus have implications for treatment
discovery,even in the absence of the marker’s sensitivity
and specificity at the levels necessary for diagnostic pur-
poses.More extensive animal model studies are neces-
sary to design such interventions,but mouse strains with
similar genetic and neurobiological features would seem
to be useful for such work.Eventually,safe treatments
that can be applied population wide may result from the
consideration of developmental processes that produce
biomarkers related to schizophrenia. ❏
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Biomarcadores precoces de psicosis
Aun no se han identificado los rasgos biológicos
que predicen el desarrollo posterior de una psico-
sis. La naturaleza compleja y multideterminada de
la esquizofrenia y de otras psicosis hace poco pro-
bable que algún biomarcador aislado sea lo sufi-
cientemente sensible y específico para identificar
con certeza sujetos que más tarde llegarán a ser psi-
cóticos. Sin embargo, la investigación genética
actual ha comenzado a identificar genes que se aso-
cian con la esquizofrenia, algunos de los cuales tie-
nen fenotipos que aparecen precozmente en la
vida. Aunque estos fenotipos tienen un bajo poder
predictor para identificar individuos que llegarán a
ser psicóticos, ellos sirven como biomarcadores de
procesos fisiopatológicos que pueden llegar a ser
los blancos de las estrategias de prevención.
Ejemplos de esto provienen del trabajo acerca del
papel del receptor nicotínico α 7 y su gen CHRNA 7
en el cromosoma 15 en la neurobiología y en la
transmisión genética de la esquizofrenia.
Marqueurs précoces de psychose
Les particularités biologiques prédictives du déve-
loppement ultérieur d’une psychose n’ont pas
encore été identifiées. La nature complexe, multi-
factorielle de la schizophrénie et d’autres psychoses
rend peu probable qu’un seul biomarqueur soit à
la fois suffisamment sensible et spécifique pour per-
mettre d’identifier sans ambiguïté les individus qui
deviendront psychotiques. Cependant, la recherche
génétique actuelle a commencé à identifier des
gènes associés à la schizophrénie, certains ayant des
phénotypes qui apparaissent précocement dans le
cours de la vie. Alors que ces phénotypes ont un
faible pouvoir prédictif pour identifier les individus
qui développeront une psychose, ils servent de bio-
marqueurs pour les processus physiopathologiques
pouvant devenir les cibles des stratégies de pré-
vention. Des exemples sont fournis par un travail
sur le rôle du récepteur α 7-nicotinique et de son
gène CHRNA7 situé sur le chromosome 15, en neu-
robiologie et dans la transmission génétique de la
schizophrénie.
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